Get started
Stoke Therapeutics, Inc.Stoke Therapeutics, Inc.Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

STOK chart


Full chart

STOK upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪677.05 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.19USD
Net income (FY)
‪−104.70 M‬USD
Revenue (FY)
‪8.78 M‬USD
Shares float
‪41.36 M‬
Beta (1Y)
1.15

Employees


Employees (FY)
110
Change (1Y)
−7 −5.98%
Revenue / Employee (1Y)
‪79.82 K‬USD
Net income / Employee (1Y)
‪−951.81 K‬USD

About Stoke Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Edward M. Kaye
Website
stoketherapeutics.com
Headquarters
Bedford
Founded
2014
FIGI
BBG00JPCBPG9
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

STOK news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of STOK is 12.86 USD — it has increased by 4.05% in the past 24 hours. Watch Stoke Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Stoke Therapeutics, Inc. stocks are traded under the ticker STOK.
STOK stock has risen by 6.72% compared to the previous week, the month change is a 5.76% rise, over the last year Stoke Therapeutics, Inc. has showed a 214.43% increase.
We've gathered analysts' opinions on Stoke Therapeutics, Inc. future price: according to them, STOK price has a max estimate of 35.00 USD and a min estimate of 17.00 USD. Watch STOK chart and read a more detailed Stoke Therapeutics, Inc. stock forecast: see what analysts think of Stoke Therapeutics, Inc. and suggest that you do with its stocks.
STOK reached its all-time high on Jan 20, 2021 with the price of 71.58 USD, and its all-time low was 3.35 USD and was reached on Oct 27, 2023. View more price dynamics on STOK chart.
See other stocks reaching their highest and lowest prices.
STOK stock is 4.53% volatile and has beta coefficient of 1.15. Track Stoke Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Stoke Therapeutics, Inc. there?
Today Stoke Therapeutics, Inc. has the market capitalization of ‪650.73 M‬, it has increased by 3.73% over the last week.
Yes, you can track Stoke Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Stoke Therapeutics, Inc. is going to release the next earnings report on Nov 13, 2024. Keep track of upcoming events with our Earnings Calendar.
STOK earnings for the last quarter are −0.46 USD per share, whereas the estimation was −0.55 USD resulting in a 16.07% surprise. The estimated earnings for the next quarter are −0.54 USD per share. See more details about Stoke Therapeutics, Inc. earnings.
Stoke Therapeutics, Inc. revenue for the last quarter amounts to ‪4.83 M‬ USD, despite the estimated figure of ‪3.70 M‬ USD. In the next quarter, revenue is expected to reach ‪3.64 M‬ USD.
STOK net income for the last quarter is ‪−25.70 M‬ USD, while the quarter before that showed ‪−26.37 M‬ USD of net income which accounts for 2.57% change. Track more Stoke Therapeutics, Inc. financial stats to get the full picture.
No, STOK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 2, 2024, the company has 110.00 employees. See our rating of the largest employees — is Stoke Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Stoke Therapeutics, Inc. EBITDA is ‪−109.90 M‬ USD, and current EBITDA margin is ‪−1.25 K‬%. See more stats in Stoke Therapeutics, Inc. financial statements.
Like other stocks, STOK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Stoke Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Stoke Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Stoke Therapeutics, Inc. stock shows the buy signal. See more of Stoke Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.